Advertisement
Advertisement
TELA
TELA Bio, Inc. Common Stock
0.87
USDSponsored
+0.01
+1.15%
Aug 07, 15:56 UTC -4
Closed
After-Market
0.87
0.00
-0.33%
TELA Earnings Reports
Positive Surprise Ratio
TELA beat 8 of 27 last estimates.
30%
Next Report
Next Week
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$20.41M
/-$0.18
Implied change from Q1 26 (Revenue/ EPS)
+7.08%
/-14.29%
Implied change from Q2 25 (Revenue/ EPS)
+1.05%
/-18.18%
TELA Bio, Inc. Common Stock earnings per share and revenue
On May 12, 2026, TELA reported earnings of -0.21 USD per share (EPS) for Q1 26, missing the estimate of -0.19 USD, resulting in a -9.37% surprise. Revenue reached 19.06 million, compared to an expected 18.97 million, with a 0.48% difference. The market reacted with a +13.07% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of -0.18 USD, with revenue projected to reach 20.41 million USD, implying an decrease of -14.29% EPS, and increase of 7.08% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
Celldex Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.07
Actual
-$0.94
Surprise
+12.79%
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Zymeworks Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.46
Actual
-$0.62
Surprise
-32.31%
Intellia Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.81
Actual
-$0.80
Surprise
+1.86%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Verastem, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.44
Actual
-$0.35
Surprise
+20.69%
ALX Oncology Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+11.08%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.01
Actual
-$0.84
Surprise
+17.53%
FAQ
What were TELA Bio, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, TELA Bio, Inc. Common Stock reported EPS of -$0.21, missing estimates by -9.37%, and revenue of $19.06M, 0.48% above expectations.
How did the market react to TELA Bio, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 13.07%, changed from $0.87 before the earnings release to $0.99 the day after.
When is TELA Bio, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for TELA Bio, Inc. Common Stock's next earnings report?
Based on 6
analysts, TELA Bio, Inc. Common Stock is expected to report EPS of -$0.18 and revenue of $20.41M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement